SCHEMBL713988

SCHEMBL713988

O=S(=O)(Nc1nccs1)c1ccc(Nc2ncccn2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.64
PKM P14618 2/20 0.64
ATM Q13315 1/20 0.64
LMNA P02545 2/20 0.63
KDM4E B2RXH2 1/20 0.63
CYP2C9 P11712 1/20 0.63
EDNRA P25101 1/20 0.63
SLC6A4 P31645 1/20 0.63
ADRA1A P35348 1/20 0.63
PRMT6 Q96LA8 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
CCNT1 O60563 2/20 0.63
CDK9 P50750 2/20 0.63
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
EGFR P00533 1/20 0.60
KDR P35968 1/20 0.60
POLB P06746 1/20 0.58
CYP1A2 P05177 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4146308 0.84 CCNT1 (0.66) ALDH1A1PKMATMLMNAKDM4E
SCHEMBL13154425 0.82 ALDH1A1 (0.71) ALDH1A1PKMATMLMNAKDM4E
Sulfadiazine SCHEMBL28117247 0.82 LMNA (0.84) ALDH1A1PKMATMLMNAKDM4E
SCHEMBL713573 0.82 CCNT1 (0.70) ALDH1A1PKMATMLMNAKDM4E
SCHEMBL13452528 0.81 MEN1 (0.71) ALDH1A1PKMATMLMNAKDM4E
Hydrochloric Acid SCHEMBL8933679 0.81 EGFR (0.60) ALDH1A1PKMATMLMNAKDM4E
SCHEMBL326633 0.81 ALDH1A1 (0.71) ALDH1A1PKMATMLMNAKDM4E
SCHEMBL712458 0.79 CCNT1 (0.61) PKMCCNT1CDK9MEN1KMT2A
Hydrochloric Acid SCHEMBL27575105 0.79 ALDH1A1 (0.69) ALDH1A1PKMATMLMNAKDM4E
SCHEMBL3066836 0.79 LMNA (0.79) ALDH1A1PKMATMLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A ALDH1A1 3333/4885PKM 2666/4885ATM 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.